UNITED STATES
                     SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                   FORM 8-K

                                 CURRENT REPORT
   Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported)     August 27, 2007

                           ON THE GO HEALTHCARE, INC.
           (Exact name of registrant as specified in its charter)

     DELAWARE                      333-61538                 98-0231687
  ----------------             --------------------    -------------------
  (State or Other                 (Commission          (IRS Employer
  Jurisdiction of                 File Number)           Identification
   Incorporation)                                                   No.)

                         85 Corstate Avenue, Unit #1
                              Concord, Ontario
                               Canada L4K 4Y2
              ---------------------------------------------------
              (Address of principal executive offices) (Zip Code)


     Registrant's telephone number, including area code:  (905) 760-2987

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))


                    ----------------------------------------

<PAGE>

ITEM 1.02       TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT.

On July 14, 2005, we entered into a convertible financing facility with Laurus
Master Fund, Ltd. for up to $5,500,000.  The facility consists of (i) a
$500,000 Secured Convertible Term Note, (ii) a $2,500,000 Secured Convertible
Minimum Borrowing Note, and (iii) a $5,000,000 Secured Revolving Note
(collectively, the "Notes").  The Notes are secured by a security interest
in substantially all of our assets.  Additionally, as part of the financing,
we issued Laurus common stock purchase warrants to purchase up to 1,420,000
shares of our common stock at a price of $0.65 per share, expiring
July 14, 2012. The facility terminates on July 14, 2008.

On January 24, 2006, we agreed to revise the financing facility with Laurus.
On May 16, 2006, we agreed to further amend the Amended and Restated Secured
Convertible Term Note (the "Term Note") so that the conversion price of $0.50
would be reduced to $0.14 for $85,000 of the principal and associated interest
and fees.  The rest of the principal of the Term Note and the interest
associated with the principal would continue to be convertible at $0.50.
On June 5, 2006 we reduced the fixed conversion price of the Term Note from
$0.50 to $0.14.  On July 11, 2007, we agreed to further amend the Term Note
to reduce the fixed conversion price of the Term Note to $0.005. The Term
Note, as amended, matures on July 14, 2008 and is convertible into our common
stock, under certain conditions, at a price of $0.005.  The Term Note has an
interest rate equal to the Wall Street Journal prime rate plus 2%.  The
interest rate will not be lower than 8% based on movements in the prime rate.
Under the terms of the Term Note, we began making monthly payments plus accrued
and unpaid interest on August 1, 2005. Under certain conditions set forth in
the Term Note, Laurus will be required to convert into shares of common stock
all or a portion of their monthly payment.  In the event that all or a portion
of the monthly payment is paid in cash, then we must pay Laurus 100% of the
cash amount.

We may prepay the Term Note by paying to Laurus a sum of money equal to one
hundred thirty percent of the Principal Amount outstanding at such time
together with accrued but unpaid interest thereon and any and all other sums
due, accrued or payable to Laurus under any portion of the facility.

On August 27, 2007 Laurus converted the remaining amount due under the Term
Note into shares of our common stock and as such the Term Note has been paid
in full in advance of its due date of July 14, 2008.

The securities described above were offered and sold to Laurus in a private
placement transaction made in reliance upon exemptions from registration
pursuant to Section 4(2) under the Securities Act of 1933 and Rule 506
promulgated thereunder.  Laurus is an accredited investor as defined in
Rule 501 of Regulation D promulgated under the Securities Act of 1933.

This report may contain forward-looking statements that involve risks and
uncertainties, including, without limitation, statements concerning our
business and possible or assumed future results of operations.  We generally
use words such as "believe," "may," "could," "will," "intend," "expect,"
"anticipate," "plan," and similar expressions to identify  forward-looking
statements. You should not place undue reliance on these forward-looking
statements.  Our actual results could differ materially from those
anticipated in the forward-looking statements for many reasons including
the risks described in our annual report on Form 10-KSB and other filings
we make from time to time filed with the Securities and Exchange Commission.
Although we believe the expectations reflected in the forward-looking
statements are reasonable, they relate only to events as of the date on
which the statements are made, and our future results, levels of activity,
performance or achievements may not meet these expectations.  We do not
intend to update any of the forward-looking statements after the date of
this document to conform these statements to actual results or to changes
in our expectations, except as required by law.

<PAGE>


ITEM 9.01   EXHIBITS

EXHIBIT
NUMBER      DESCRIPTION

4.1         Amended and Restated Secured Convertible Term Note, dated
            January 13, 2006 (included as Exhibit 4.1 to the Form 8-K filed
            January 30, 2006 and incorporated herein by reference).

4.2         Omnibus Amendment, dated July 11, 2007 (included as exhibit 4.7
            to the Form 8-K filed July 17, 2007 and incorporated herein by
            reference).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date    August 29, 2007



On the Go Healthcare, Inc.
-------------------------------
(Registrant)



/s/ Stuart Turk
-------------------------------
(Signature)

Name: Stuart Turk
Title: Chief Executive Officer
       and President



<PAGE>
[{"type": "8-K", "sequence": "1", "filename": "laurus8k_aug292007paid.txt", "description": "LAURUS NOTE PAID AUGUST 27 2007", "secsgml_size_bytes": 6981}]
{"company-data": {"conformed-name": "ON THE GO HEALTHCARE INC", "cik": "0001126302", "assigned-sic": "5045", "irs-number": "980231687", "fiscal-year-end": "0731"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-61538", "film-number": "071087692"}, "business-address": {"street1": "85 CORSTATE AVENUE UNIT 1", "city": "CONCORD ONT. CANADA", "state": "A6", "zip": "L4K 4Y2", "phone": "905 669 7979 EXT 400"}, "mail-address": {"street1": "85 CORSTATE AVENUE UNIT 1", "city": "CONCORD ONT. CANADA", "state": "A6", "zip": "L4K 4Y2"}}
UNITED STATES
                     SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                   FORM 8-K

                                 CURRENT REPORT
   Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported)     August 27, 2007

                           ON THE GO HEALTHCARE, INC.
           (Exact name of registrant as specified in its charter)

     DELAWARE                      333-61538                 98-0231687
  ----------------             --------------------    -------------------
  (State or Other                 (Commission          (IRS Employer
  Jurisdiction of                 File Number)           Identification
   Incorporation)                                                   No.)

                         85 Corstate Avenue, Unit #1
                              Concord, Ontario
                               Canada L4K 4Y2
              ---------------------------------------------------
              (Address of principal executive offices) (Zip Code)

     Registrant's telephone number, including area code:  (905) 760-2987

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

                    ----------------------------------------
ITEM 1.02       TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT.

On July 14, 2005, we entered into a convertible financing facility with Laurus
Master Fund, Ltd. for up to $5,500,000.  The facility consists of (i) a
$500,000 Secured Convertible Term Note, (ii) a $2,500,000 Secured Convertible
Minimum Borrowing Note, and (iii) a $5,000,000 Secured Revolving Note
(collectively, the "Notes").  The Notes are secured by a security interest
in substantially all of our assets.  Additionally, as part of the financing,
we issued Laurus common stock purchase warrants to purchase up to 1,420,000
shares of our common stock at a price of $0.65 per share, expiring
July 14, 2012. The facility terminates on July 14, 2008.

On January 24, 2006, we agreed to revise the financing facility with Laurus.
On May 16, 2006, we agreed to further amend the Amended and Restated Secured
Convertible Term Note (the "Term Note") so that the conversion price of $0.50
would be reduced to $0.14 for $85,000 of the principal and associated interest
and fees.  The rest of the principal of the Term Note and the interest
associated with the principal would continue to be convertible at $0.50.
On June 5, 2006 we reduced the fixed conversion price of the Term Note from
$0.50 to $0.14.  On July 11, 2007, we agreed to further amend the Term Note
to reduce the fixed conversion price of the Term Note to $0.005. The Term
Note, as amended, matures on July 14, 2008 and is convertible into our common
stock, under certain conditions, at a price of $0.005.  The Term Note has an
interest rate equal to the Wall Street Journal prime rate plus 2%.  The
interest rate will not be lower than 8% based on movements in the prime rate.
Under the terms of the Term Note, we began making monthly payments plus accrued
and unpaid interest on August 1, 2005. Under certain conditions set forth in
the Term Note, Laurus will be required to convert into shares of common stock
all or a portion of their monthly payment.  In the event that all or a portion
of the monthly payment is paid in cash, then we must pay Laurus 100% of the
cash amount.

We may prepay the Term Note by paying to Laurus a sum of money equal to one
hundred thirty percent of the Principal Amount outstanding at such time
together with accrued but unpaid interest thereon and any and all other sums
due, accrued or payable to Laurus under any portion of the facility.

On August 27, 2007 Laurus converted the remaining amount due under the Term
Note into shares of our common stock and as such the Term Note has been paid
in full in advance of its due date of July 14, 2008.

The securities described above were offered and sold to Laurus in a private
placement transaction made in reliance upon exemptions from registration
pursuant to Section 4(2) under the Securities Act of 1933 and Rule 506
promulgated thereunder.  Laurus is an accredited investor as defined in
Rule 501 of Regulation D promulgated under the Securities Act of 1933.

This report may contain forward-looking statements that involve risks and
uncertainties, including, without limitation, statements concerning our
business and possible or assumed future results of operations.  We generally
use words such as "believe," "may," "could," "will," "intend," "expect,"
"anticipate," "plan," and similar expressions to identify  forward-looking
statements. You should not place undue reliance on these forward-looking
statements.  Our actual results could differ materially from those
anticipated in the forward-looking statements for many reasons including
the risks described in our annual report on Form 10-KSB and other filings
we make from time to time filed with the Securities and Exchange Commission.
Although we believe the expectations reflected in the forward-looking
statements are reasonable, they relate only to events as of the date on
which the statements are made, and our future results, levels of activity,
performance or achievements may not meet these expectations.  We do not
intend to update any of the forward-looking statements after the date of
this document to conform these statements to actual results or to changes
in our expectations, except as required by law.
ITEM 9.01   EXHIBITS

EXHIBIT
NUMBER      DESCRIPTION

4.1         Amended and Restated Secured Convertible Term Note, dated
            January 13, 2006 (included as Exhibit 4.1 to the Form 8-K filed
            January 30, 2006 and incorporated herein by reference).

4.2         Omnibus Amendment, dated July 11, 2007 (included as exhibit 4.7
            to the Form 8-K filed July 17, 2007 and incorporated herein by
            reference).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date    August 29, 2007

On the Go Healthcare, Inc.
-------------------------------
(Registrant)

/s/ Stuart Turk
-------------------------------
(Signature)

Name: Stuart Turk
Title: Chief Executive Officer
       and President